TABLE 2.
Treatment characteristics
| Oxaliplatin (n = 27) |
Cisp latin (n = 19) |
|||
|---|---|---|---|---|
| No. Patients, n (%) | No. Patients, n (%) | P | ||
| Retreated with carboplatin | No | 18 (66.7) | 15 (79.0) | 0.51 |
| Yes | 9 (33.3) | 4 (21.1) | ||
| Response to therapy | Complete response | 9 (34.6) | 6 (31.6) | 0.46 |
| Progressive disease | 4 (15.4) | 6 (31.4) | ||
| Persistent disease | 13 (50.0) | 7 (36.8) | ||
| Unknown | 1 | 0 | ||
| Hypersensitivity reaction | Yes | 2 (7.4) | 0 (0) | 0.5 |
| No | 25 (92.6) | 19 (100) | ||
| No. carboplatin cycles before HSR | Mean | 7.2 | 9.1 | 0.93 |
| Median | 6 | 7.5 | ||
| Range | 1–21 | 1–27 | ||
| SD | 4.3 | 8 | ||
| Carboplatin cumulative dose, mg | Mean | 1037.6 | 707.8 | 0.49 |
| Median | 980 | 686 | ||
| Range | 158–2940 | 73–2152 | ||
| SD | 662 | 579.6 | ||
| No. platinum cycles | Mean | 7.6 | 7.3 | 1 |
| Median | 6 | 6 | ||
| Range | 1–21 | 1–22 | ||
| SD | 4.1 | 5.8 |